Core Viewpoint - INVO Fertility is now exclusively focused on the growing fertility market following the divestiture of a majority stake in NAYA Therapeutics, aiming to expand access to advanced fertility treatments and capitalize on supportive policy shifts in the U.S. [1][3] Financial Performance - Revenue for Q1 2025 was $1,637,185, representing a 4% increase from $1,576,286 in Q1 2024 [6] - Consolidated clinic revenue increased by 5% to $1,621,553 compared to $1,537,199 in the previous year [6] - Total revenue from all clinics, including consolidated and equity method clinics, was $1,943,763, up 4% from $1,869,513 [6] - The net loss for the quarter was $(17.4) million, significantly higher than $(1.6) million in the prior year, primarily due to a non-cash impairment charge of $14.6 million related to NAYA Therapeutics [6][11] - Adjusted EBITDA was $(606,551), compared to $(427,467) in the previous year, excluding losses from NAYA TX [6][7] Strategic Focus - The company has sharpened its focus on its core mission as a fertility company, implementing initiatives to accelerate organic clinic growth and exploring acquisitions for expansion [3][4] - The divestiture of NAYA TX is expected to allow both INVO Fertility and NAYA TX to concentrate on their respective opportunities, with INVO Fertility aiming for cash flow break-even and profitability [4][3] Business Model - INVO Fertility is dedicated to expanding assisted reproductive technology (ART) care, focusing on building, acquiring, and operating fertility clinics, including INVO Centers that offer the intravaginal culture (IVC) procedure [8] - The IVC procedure, enabled by the proprietary INVOcell medical device, provides a more natural and affordable experience compared to traditional IVF, with comparable results at a lower cost [8]

Financial Data and Key Metrics Changes - First quarter revenue grew 16.5% to $324 million, primarily due to an increase in the number of clients and covered lives compared to the previous year [15] - Adjusted EBITDA increased by 15% to $58 million, with an adjusted EBITDA margin of 17.8%, slightly down from the previous year [22][28] - Net income was $15.1 million or $0.17 per diluted share, compared to $16.9 million or $0.17 per share in the prior year [22] Business Line Data and Key Metrics Changes - Fertility revenue increased 22% to $206 million, while pharmacy revenue grew 9% to $118 million [20] - ART cycles reached a record high of 16,160, reflecting a 9% growth year-over-year [19] Market Data and Key Metrics Changes - The CDC reported record low birth rates for women aged 25 and younger, while rates for women aged 30 to 44 continue to rise, indicating a shift in family planning trends [6][7] - Over 51% of all births in the U.S. now come from women aged 30 or older, highlighting the increasing need for fertility and maternity solutions [8] Company Strategy and Development Direction - The company is focusing on expanding its product portfolio and enhancing member experience, particularly in women's health and family building [5][9] - New services in maternity, postpartum, and menopause are expected to contribute up to 10% of revenue by 2028, although significant contributions are not anticipated in the near term [13][14] Management's Comments on Operating Environment and Future Outlook - Management raised full-year guidance, projecting revenue between $1.185 billion and $1.235 billion, reflecting growth of 1.5% to 5.8% [27] - The company expects continued member engagement at historical levels, despite potential variability in activity and treatments [25] Other Important Information - The company generated nearly $50 million in operating cash flow in the first quarter, nearly double the prior year period [23] - Total working capital as of March 31 was $331 million, with $256 million in cash and no debt [24] Q&A Session Summary Question: Historical seasonality of cycles per utilizer - Management indicated that guidance reflects uncertainty rather than a change in normal seasonality [30] Question: Drivers of gross margin expansion - Management noted that last year's revenue shortfall affected margins, and while they expect gross margin expansion for the full year, investments may impact margins [31][33] Question: 2026 selling season and RFP process - Management confirmed that they are not seeing a slowdown in RFP activities and are targeting to add at least 1 million new lives each year [38][43] Question: Incremental adjusted EBITDA margin - Management explained that the lower margin is due to investments in platform and product expansion, which are expected to impact the P&L this year [44] Question: Interest in new modules - The menopause product is seeing higher engagement due to a larger addressable audience compared to maternity products [47] Question: Impact of tariffs on costs - Management stated that existing tariffs have not significantly impacted costs, and potential tariffs on pharmaceuticals are not expected to affect their operations [53] Question: Pricing benefits in ART cycles - Management clarified that growth is driven by engagement and activity rather than pricing [68]

Core Insights - NewGen has rebranded its MicroSort technology to NewGenSort, integrating it into its product offerings to enhance reproductive solutions in Asia [1][4] - NewGenSort technology allows for the separation of X and Y chromosome-bearing sperm cells, facilitating family planning and prevention of genetic diseases [2][3] Company Overview - NewGenIvf Group Limited is a comprehensive fertility services provider in Asia, offering a range of fertility treatments to couples and individuals [5] - The company operates clinics in Thailand, Cambodia, and Kyrgyzstan, providing services such as infertility treatments, egg and sperm donation, and surrogacy [5] Technology Applications - NewGen plans to utilize its sperm-sorting technology through two applications: MicroSort for gender selection and MacroSort for addressing male reproductive challenges [3] - MicroSort enables couples to balance family composition, while MacroSort focuses on avoiding sex-linked genetic disorders [3] Strategic Vision - The integration of NewGenSort is seen as a pivotal advancement for the company, expected to accelerate growth and expand market share across Asia [4] - The technology aims to provide personalized reproductive solutions, enhancing the overall family health and prosperity for clients [4]

Core Insights - INVO Fertility, Inc. reported record revenue of $6.5 million for 2024, a 116% increase compared to 2023, driven by the performance of its fertility clinics across the U.S. [4] - The company is refocusing on its core fertility operations following the decision to divest a majority stake in NAYA TX, aiming to capitalize on favorable market trends and increasing public demand for fertility care [4][5] - The U.S. fertility services market is expected to grow due to rising infertility rates and increasing acceptance of assisted reproductive technologies (ART) [7] Q4 2024 Financial Highlights - Revenue for Q4 2024 was $1,685,966, a 22% increase from $1,381,754 in Q4 2023 [6] - Consolidated clinic revenue from the INVO Center in Atlanta and the fertility clinic in Madison increased by 24% to $1,687,300 [6] - Adjusted EBITDA for Q4 2024 was $(450,908), an improvement from $(1.0) million in the prior year [6][14] 2024 Financial Highlights - Total revenue for 2024 reached $6,532,000, up 116% from $3,020,575 in 2023 [6] - Consolidated clinic revenue increased by 125% to $6,450,431 compared to $2,862,574 in 2023 [6] - Net loss for 2024 was $(9.1) million, compared to $(8.0) million in 2023, attributed to the addition of NAYA Therapeutics and merger costs [6] Management Commentary - The CEO highlighted the streamlined operating structure aimed at achieving positive cash flow and the successful expansion into new markets [4] - The company is actively pursuing expansion opportunities in response to declining U.S. fertility rates and rising demand for fertility solutions [4] Market Context - The global fertility services market is projected to grow, driven by rising infertility rates and delayed parenthood [7] - The Centers for Disease Control and Prevention reported a 50% increase in ART-conceived births from 2012 to 2021, with ART now accounting for 2.3% of all births in the U.S. [7]

Company Overview - INVO Fertility, Inc. is a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition, and operation of fertility clinics [1][4] - The company will begin trading under the new Nasdaq ticker symbol "IVF" on April 28, 2025, reflecting its concentration on the fertility care market [1][3] Strategic Focus - The company has made a strategic decision to separate its fertility and oncology businesses into distinct operations, which is part of its broader strategy to enhance its focus on fertility services [2][3] - CEO Steve Shum emphasized the company's commitment to building, acquiring, and operating fertility clinics in the U.S., as well as its focus on innovative reproductive services and technologies [3] Product and Services - INVO Fertility's principal commercial strategy includes the operation of "INVO Centers" that primarily offer the intravaginal culture (IVC) procedure enabled by its proprietary INVOcell medical device [4] - The IVC procedure is designed to provide a more natural, intimate, and affordable experience compared to traditional assisted reproductive technology (ART) treatments, potentially delivering comparable results at a lower cost [4]

Core Viewpoint - NewGenIvf Group Limited has filed its annual report for the fiscal year ended December 31, 2024, indicating a strong liquidity position and strategic opportunities in the fertility services market in Asia [1][2]. Company Overview - NewGen is a comprehensive fertility services provider in Asia, dedicated to helping couples and individuals access fertility treatments [3]. - The company operates clinics in Thailand, Cambodia, and Kyrgyzstan, offering a full suite of services including infertility treatments, egg and sperm donation, and surrogacy [3]. - The management team has over a decade of experience in the fertility industry [3]. Financial Position - The company reported having $2.48 million in cash and a cash deposit of $1 million, significantly exceeding its current market capitalization of $1.48 million [2]. - NewGen has strengthened its balance sheet by settling all outstanding promissory notes and converting several mandatory additional notes into equity [2]. - The company has access to a $100 million equity line of credit facility, with approximately $7.1 million drawn to date, positioning it well for future strategic opportunities [2].

Core Points - The Wyatt Foundation and The Conceive Fertility Foundation launched a 2025 IVF grant program during National Infertility Awareness Week, offering $15,000 grants to five individuals or couples needing fertility care [1][6] - CooperSurgical is participating for the first time, providing an additional $1,000 for preimplantation genetic testing (PGT) for each grant recipient [2][3] - The program aims to raise awareness about infertility, alleviate financial burdens, and support research for more affordable fertility care options [1][4] Company Overview - The Wyatt Foundation is a 501(c)(3) nonprofit organization focused on helping individuals and couples achieve family-building dreams through assisted reproductive technology (ART) by reducing financial barriers to IVF [8][9] - The Conceive Fertility Foundation, founded by Katy Mimari, aims to support individuals affected by infertility through education and grants, with a portion of Caden Lane's profits funding its mission [4][10] - CooperSurgical, a leader in fertility and women's health for nearly 35 years, is dedicated to providing innovative ART and genomic solutions to enhance fertility care [14][15] Program Details - The IVF grant program covers approximately the cost of one IVF cycle, excluding medication fees, with an additional $1,000 towards PGT with ICSI [5] - Grant recipients can choose their clinic, with those within The Prelude Network receiving a 10% discount on fertility services [5][11] - Applications for the grant are open from April 21, 2025, to June 23, 2025, with recipients announced on July 1, 2025 [6]

Core Viewpoint - NewGenIvf Group Limited has secured $5.2 million in strategic funding to support its expansion into the UAE, with plans to establish a fertility clinic in Dubai, leveraging advanced technology and aiming to serve a diverse patient base [1][5][6] Funding Arrangements - The company has entered into two funding arrangements with an investor, with the potential to raise a total of up to $30.8 million [1] - The fourth tranche of debt financing was completed, involving a senior convertible note of $2 million with an interest rate of 14.75% per annum [2] - A new Securities Purchase Agreement was established, allowing for the sale of additional convertible notes not exceeding $25.6 million [3] Expansion Plans - The funding will be utilized to establish a state-of-the-art fertility clinic in Dubai, which will offer a comprehensive suite of services including IVF with gender selection, egg donation, and surrogacy [5] - The clinic aims to attract patients from the UAE, EU countries, and neighboring regions, particularly India, where there is significant demand for fertility services [5] - Construction of the facility is expected to begin in the second quarter of 2025, with an opening targeted for the fourth quarter of the same year [5] Company Background - NewGen is a comprehensive fertility services provider in Asia, with clinics located in Thailand, Cambodia, and Kyrgyzstan, offering a full suite of infertility treatments [7] - The company is dedicated to increasing access to fertility treatments and has a management team with over a decade of experience in the fertility industry [7]

Core Viewpoint - NewGenIvf Group Limited has terminated its binding term sheet with European Wellness Investment Holdings Limited regarding a proposed reverse merger due to EWIHL's failure to deliver required draft audited financial statements by the deadline [1][2]. Company Overview - NewGen is a comprehensive fertility services provider in Asia, offering a range of fertility treatments to couples and individuals facing infertility challenges [4]. - The company operates clinics in Thailand, Cambodia, and Kyrgyzstan, providing services such as assisted reproductive technology, egg and sperm donation, and surrogacy [4]. Transaction Details - The proposed reverse merger would have resulted in EWIHL holding approximately 61.6% of NewGen's equity [2]. - The completion of the merger was contingent upon due diligence, delivery of draft audited financials for 2023 and 2024, and negotiation of a definitive agreement [2]. Management Commentary - The CEO of NewGen expressed confidence in the company's ability to pursue other growth opportunities despite the termination of the merger [3]. - The management team remains focused on executing the core business strategy and exploring avenues to create shareholder value, including recent acquisitions and services like lifetime egg-freezing [3].

Company Overview - NewGenIvf Group Limited is a comprehensive fertility services provider in Asia, dedicated to helping couples and individuals access fertility treatments [5] - The company operates clinics in Thailand, Cambodia, and Kyrgyzstan, offering a full suite of services including infertility treatments, assisted reproductive technology, egg and sperm donation, and surrogacy [5] - BOBCARE FERTILITY GROUP LLC is a leading reproductive health and assisted reproduction service platform in China, focusing on high-quality assisted reproduction services and industry innovation [6] Strategic Collaboration - NewGen has entered into a strategic collaboration agreement with BOBCARE to jointly develop fertility services in the Kyrgyzstan market [1][2] - The partnership aims to combine NewGen's technical expertise with BOBCARE's market resources, enhancing both companies' competitive positions in Kyrgyzstan [2] - Initiatives under this collaboration include improving clinical protocols, patient management systems, knowledge exchange, coordinated marketing, and developing specialized fertility treatment options [2] Market Potential - Kyrgyzstan is identified as a developing market for fertility services in Central Asia, with a young population and increasing demand for advanced reproductive technologies [3] - The collaboration aligns with the economic cooperation between China and Kyrgyzstan, enhancing trade and investment opportunities under the "One-Belt-One-Road" framework [3] - BOBCARE's recent expansion in Kyrgyzstan provides valuable local market insights and established networks, while NewGen contributes international experience in fertility treatments [3] Leadership Insights - The CEO of NewGen emphasized that the collaboration represents a strategic opportunity to extend services to an emerging market with significant growth potential [4] - BOBCARE's CEO highlighted the partnership as a significant step in their globalization efforts, aiming to introduce elite reproductive healthcare professionals and technologies to Central Asia [4]